Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -3.38% 7.15 4,733,174 11:09:01
Bid Price Offer Price High Price Low Price Open Price
7.10 7.20 7.40 7.05 7.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.12 28
Last Trade Time Trade Type Trade Size Trade Price Currency
11:32:29 O 3,550 7.119 GBX

Hemogenyx Pharmaceuticals (HEMO) Latest News

More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
26/5/202011:28HEMO 2020/21 Discussion MODERATED2,641
26/5/202007:44HEMO ANTIBODIES Viruses, Disease X Pathogens Bloods stem cells13
23/5/202021:36HEMO INVESTORS ONLY460

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 7.40p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 4.85p and a 12 week average price of 1.05p.
The 1 year high share price is 15.15p while the 1 year low share price is currently 1.05p.
There are currently 397,921,969 shares in issue and the average daily traded volume is 8,483,333 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £28,650,381.77.
mms98: Tully, if you right clicked and opened the post on a new link it works. Here is a copy. Hemogenyx Pharmaceuticals (LON: HEMO) up over 260% as it searches for COVID antibodies Companies that can as good as guarantee investor interest in these crazy times are, besides those producing toilet paper and sanitizers, companies involved in some sort of solution to the coronavirus pandemic. London-listed biopharma firm Hemogenyx Pharmaceuticals (LON: HEMO) is no exception. Still time to enter The Armchair Trader’s stock picking competition and donate to the NHS The relatively small biotech company has been developing treatments for blood cancers and autoimmune diseases over the last seven years but came to investors’ attention last week when it announced that it its looking to discover antibodies that can fight Covid 19. Hemogenyx Pharmaceuticals and humanised mice Hemogenyx Pharmaceuticals is using its proprietary ‘humanised mice’ which have been developed for previous research to focus on coronavirus antibodies. While some people infected by Covid 19 shake the disease off with almost no symptoms others fall severely ill. Hemogenyx’s team is now running a pilot project to figure out why that is the case, and to substantiate it with data. “We are using our new generation of humanised mice to discover human neutralising antibodies that were developed by convalescent patients, patients that fell ill and developed antibodies against this virus,” Hemogenyx chief executive and co-founder Vladislav Sandler told The Armchair Trader today. “Once discovereed, the company plans to clone the antibodies and develop them into a drug.” The time frame for this? As soon as possible, says Sandler. The Hemogenyx share price rocketed 260% in the space of a week, rising from around 2 pence last Friday to a high of 15.1 this week. Given its small cap nature – is has a market capitalization of £36m – investor interest generated so much price movement this week that there have been two price monitoring extensions on the share per day over the last few days. Research facility in coronavirus central The firm runs a state of the art research facility in what is now coronavirus central: New York City, and has not stopped work throughout the outbreak of the pandemic. Even without its COVID 19-related work, Hemogenyx Pharmaceuticals interests us because of its expertise in stem cell-related solutions for severe blood diseases and its focus on pre-clinical stage medicines and treatments for autoimmune diseases. Autoimmune conditions such as lupus, type 1 diabetes and multiple sclerosis are unfortunately on the rise. There is no good explanation as to why, but this type of disease is about three times more common now than only a few decades ago, and yet is fairly costly to treat because it requires life-long medication. Hemogenyx Pharmaceuticals already has good links with the rest of the biotech industry and is collaborating with partners like Johnson and Johnson, the University of Oxford and LakeParma on various projects. This will position it as an interesting investment not only in the short term but also once the corona dust has settled. Regards MMS98 Credit
tidy 2: Hemogenyx (HEMO): A Covid-19 Cure Instead Of Just A Vaccine? #HEMOA small laboratory in Brooklyn may at first glance appear to be an unlikely location for potentially transformational breakthroughs in blood diseases, or these days, Covid-19. However, such an assumption may not be counting on the inventive scientific brain of Dr Vladislav Sandler. CEO of Hemogenyx.hemoIn fact, he runs a tight ship, both in terms of cost and the number of personnel. That Dr Sandler's company has been punching above its weight in recent years is due not only to his direct efforts. Backed by a strong advisory team, the £23m market cap group has access to the best research facilities and resources courtesy of its big pharma collaborations.Of course, so much currently in the biotech / pharma space is centred around hopes of Covid-19 being conquered. The logical approach here is to employ existing work on viruses and see whether it can be applied to this new strain? In this respect it is interesting note that previous research with measles appears to be useful. Indeed, rather in the way that Cowpox led to the demise of Smallpox, it may be that Measles helps in the fight against Covid-19. But this trail gets better.Whereas Edward Jenner's achievement was a vaccine against Smallpox, we have the possibility of Hemogenyx being able to develop a cure for Covid-19, something not yet on the map in terms of the pharma Gold Rush in this space. This will no doubt cheer the anti-vaxxer conspiracy theorists, but lead us to a logical conclusion to the whole coronavirus saga: a cure for Virus X. The implication being that the research at Hemogenyx could offer a cure not only for the current pandemic, but develop one for future virus strains yet to be seen.As well as this there is the possibilty of being able to drill down into some of the characteristics of Covid-19, and one of its great mysteries: why some of us are symptomless and others are in receipt of a potentially deadly pathogen? Ongoing autoimmune disease research at Hemogenyx could provide answers, and show us that rather than the company being opportunistic in the face of the current pandemic, there is actually a genuine humanitarian angle to the work in progress over and above the science.But for those concerned that somehow Dr Sandler and his team are veering away from the day job, blood cancer treatments and therapies are now being addressed on not one but two fronts: CDX antibodies and CAR-T therapies. Clearly, having two treatment routes for the same ailment is better both for the patient and the commercial opportunities down the line at Hemogenyx, something the recent share price spike will have alerted many pharma sector fans to in recent weeks. This is also the backbone for the group should the current sector focus on Covid-19 fade.
tullynessle: Noting reports in the media that: i. future immunity is not assured for those who have contracted Covid-19. and ii. there is a risk that the current Covid-19 virus may mutate iii. there does not appear to be a Covid-19 vaccine or drug to manage its symptoms at this time, or in the near future. IMO, it is imperative that over the short and longer term, the technology contemplated by Hemogenyx, and described in the paragraph at "Extract" below, is successful, (not only as applicable to Covid-19 but to potentially, "a host of viral pathogens" It should be noted that it appears Hemogenyx's patented "ApbHC humanized mice" will be an integral component of HEMOs study. I own shares in HEMO / DYOR Extract: "In addition, the study will aim to demonstrate how Hemogenyx's technology can be deployed rapidly in emergencies in order to discover human neutralizing antibodies against a host of viral pathogens, including what infectious disease experts in the bioprotection and biodefense sectors call "Disease X", meaning as-yet unknown viruses that may represent a similar or greater threat than the one presented by COVID-19." Hemogenys - RNS Hemogenyx Pharmaceuticals PLC COVID-19 Project Initiated 22/04/2020 Hemogenyx to use its advanced humanized mice to develop potential treatments for COVID-19. Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is deploying its groundbreaking research and technologies to develop potential treatments for COVID-19. News Release continues.....
tullynessle: Hemogenyx provide details of two potential applications for their ApbHC humanized mice and other in-house technology, noting that this " development is an application of the Company's existing work, taking place alongside its long-term development of new treatments for blood and autoimmune diseases, which remain on track." Extract 1: With the outbreak of COVID-19, the Company concluded that it would potentially be applicable to the SARS-CoV-2 virus. As part of its studies, Hemogenyx will transplant cells from blood samples from patients who are either recovering or have already recovered from COVID-19 into its ApbHC humanized mice. The process will allow the Company's scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of COVID-19. Extract 2: "In addition, the study will aim to demonstrate how Hemogenyx's technology can be deployed rapidly in emergencies in order to discover human neutralizing antibodies against a host of viral pathogens, including what infectious disease experts in the bioprotection and biodefense sectors call "Disease X", meaning as-yet unknown viruses that may represent a similar or greater threat than the one presented by COVID-19." Hemogenyx - RNS Hemogenyx Pharmaceuticals PLC COVID-19 Project Initiated 22/04/2020 11:00am Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is deploying its groundbreaking research and technologies to develop potential treatments for COVID-19. Using its humanized mice, the Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), which were developed to model blood and autoimmune diseases and to test treatments, Hemogenyx will seek to discover human neutralizing antibodies - antibodies that are typically developed by the human immune system to neutralize invading viral pathogens - that could be used to fight SARS-CoV-2 (the virus that causes COVID-19) infections. RNS continues......
bunz3: ncyt share price moving back up buyers loading there again like how hemo share price going today
tullynessle: In two RNSs issued by Hemogenyx, (24Jun19 & 30Sep19), the Company indicates that the directors believe that ApbHC could be used in Biodefense Applications - see below. It would be useful to shareholders if said Directors provided some colour to that statement, basically: i. What is the Market - describe? ii. What is the Hemogenyx technology that can be launched in that Market? iii. What is the size of the Market - range of potential Clients / $Value? iv. How does the Hemogenoyx technology work? v. Who else competes in the same Market? vi. Is Hemogenyx ready to launch into the contemplated Market - is its technology ready? vii. Does the Hemogenyx contemplated technology have a role in neutralising the Coronovirus threat? viii.Why is there an absence of any detail concerning the potential use of Hemogenyx technology for a biodefense application? Anyone in contact with Dr Sandler or other contact within the Company. 24 June 2019 Hemogenyx Pharmaceuticals plc Extract: "The Directors also believe that the ApbHC could potentially be used as a tool for the rapid development and/or isolation of human antibodies against unknown human-specific pathogens (biodefense applications)." ======================= Hemogenyx Pharmaceuticals PLC Half-year Report 30/09/2019 7:01am " The Directors also believe that the ApbHC could potentially be used as a tool for the rapid development and/or isolation of human antibodies against unknown human-specific pathogens (biodefence applications)."
marie1980: Fair point about ramping, Dave. Good information. About hemo share price, I think during spike there will be huge volume as history suggests and that’s the time we should get out. So need to keep an eye on this share daily. But now as since I’ve decided to stick with 1-2 years of time, I will stick with it and buy should she test lower. One thing is sure and I think everyone should agree that if in 2020 if no news for IND or phase 1 then 😢
bc4: Let me put it in to perspective on the 10th of June HEMO share price was about 2.5p it is now 3.15p so take no notice of the muppet
pwhite73: dave4545 - "Killing the market and full time deramper vultures like pwhite clean up" Wrong never shorted a share in my life and PIs generally cannot short AIM and micro-cap stocks only institutions can. What I have learned over the years is do not hold AIM/micro-cap stocks long term. If you do you will pay the price with diluted placings, warrants, options, conversion loans, death spiral financing and eventually suspension and cancellation. You trade these stocks on a daily or weekly basis. I have a particular interest in bio-pharma stocks because these are the ones that can really motor if the markets believe their story. I check the ADVFN 'Toplists' daily to look at the biggest percentage risers and fallers. I normally base my trades around these. Hemo came onto my radar again as it was a big riser for 30/05/2019. I had previously noted that Hemo could never seem to hold onto any gains, that is when I really started taking a look at the company. The cracks and fissures that are in PYC and ERX can be found in Hemo. It doesn't really have anything to re-rate it. True to form Hemo share price has collapsed again. But it will rise again on the next positive RNS and fall again as day traders pile in and out whilst the market professionals short the stock.
pwhite73: Couple of other things. Only 27% of the company's shares are in free float. 73% are held by directors and institutions. Some PIs think the less shares available the more they are sought after a bit like gold nuggets. It doesn't necessarily work like that. The less shares available the wider the spread and the more illiquid the stock can be. The shares ended up 25% on the week but there were no trades on 28/05/2019 and the 29/05/2019. Had it not been for the news on 30/05/2019 I doubt a single share would have traded on all week. The previous week only 19 shares were traded all week!!. If you want a real comparison with Hemo then don't look at OBD look at PYC. Another biotech company developing software to assist in the detection and elimination of cancer. The company has been listed since 2004 and within the last 15 years the share price has done nothing. Its had its peaks like Hemo but has always returned to its base of 2p - 3p range. In Nov 2017 the share price went from 1p to 34P in a matter of three days as PIs misinterpreted an RNS. PYC had to correct the markets and the price plunged back to base. Hemo's problems are identical to PYC's. PYC has an impeccable list of employees, Professors and doctors. It has a who's who list of partnerships including Eli Lily and Merck. It has won prestigious awards and received government grants at the national and European level. It has had its research, findings and technology published in medical journals. But like Hemo there is no definite evidence to suggest its technology facilitates the elimination of cancer. PYC listed at 2p on 20/12/2004. Fifteen years on the share price is at 3p. There is something else you need to understand. A lot of these so called biotech companies are little more than research laboratories of universities masquerading as Plcs to raise finance on capital markets. This is the case with PYC and Hemo. PYC is really an off shoot laboratory of Oxford University and Hemo is really an off shoot laboratory of State of New York Medical Centre. Both companies share the same address as their respective universities. If you think the markets are suddenly going wake up to the potential of Hemo and re-rate the stock you are wrong big time. Hemo listed on 05/10/2017 at 3.5p . Two years on the share price is at 2.80p
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200526 10:53:28